Summary of Coronavirus Society News – Sinovac Covid-19 Vaccine Recall Less Effective Against Omicron – South Africa Approves Janssen Covid-19 Recall











Summary of Coronavirus Society News – Sinovac Covid-19 Vaccine Recall Less Effective Against Omicron – South Africa Approves Janssen Covid-19 Recall
















Join Our Newsletter – Get important industry news and analysis sent to your inbox – sign up for our email newsletter here

X


A booster dose of Sinovac The Covid-19 vaccine after a two-shot regimen does not provide adequate protection against the rapidly spreading Omicron variant, a lab study has found. The study was carried out by a team of researchers from Hong Kong University and the Chinese University of Hong Kong, Reuters reported. The number of samples used in the study was not disclosed. The study also found that the Pfizer-BioNTech vaccine was more effective in neutralizing the Omicron variant.

South African Health Products Authority (SAHPRA) approved Covid-19 vaccine Janssen (Ad26.COV2.S) as a second dose or as a booster after evaluation of the safety and efficacy data. According to a statement from the SAHPRA, the Janssen vaccine can be given as a booster at least two months after the primary series with an approved mRNA vaccine. The clearance comes after Janssen submitted an application earlier this month requesting a change in the dosage regimen of the Janssen vaccine.

Novavax and SK biosciences have agreed to extend their collaboration and licensing agreements for the Covid-19 vaccine based on NVX-CoV2373 recombinant protein nanoparticles. As agreed, SK bioscience will reserve additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373 until next year. The arrangement may be extended in the future. Previously, SK Bioscience signed an Advance Purchase Agreement (APA) to deliver 40 million doses of NVX-CoV2373 to South Korea.



Comments are closed.